Givaudan stock faces legal risk as US price-fixing case advances

Published on 11/11/2026 at 18:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Givaudan stock faces a US price-fixing case after a judge allowed claims against fragrance-ingredients makers to proceed. Liability remains unresolved.

Legal pressure meets operating execution

A US federal judge allowed price-fixing claims involving Givaudan and Symrise to move toward trial.
The ruling addresses the sufficiency of the allegations and does not establish liability or financial damages.
Givaudan's next scheduled full-year results are due on January 27, 2027.

Givaudan, CH0010645932, Illustration mit AI erstellt.

Givaudan stock faces a new legal-risk angle after a US federal judge allowed price-fixing claims involving Givaudan and Symrise to move toward trial. The development was reported by AD HOC NEWS on Wednesday, November 11, 2026.

Claims advance without liability finding

Judge William J. Martini of the US District Court for the District of New Jersey said plaintiffs had adequately alleged price-fixing under the Sherman Act and state antitrust laws, according to the report. He denied the defendants' motion for judgment on the pleadings.

The judge said the alleged conduct should be assessed as horizontal price-fixing between competitors at the same market level. The procedural decision allows the claims to continue and potentially reach trial, but it does not establish that Givaudan or Symrise inflated prices.

Legal risk meets operating focus

The case adds a litigation risk to Givaudan's operating story. The company reported nine-month 2026 sales of 5,891 million Swiss francs in October, while recent investor attention has focused on stronger Fragrance and Beauty momentum and slower Taste & Wellbeing progress.

Givaudan stock traded at 4,430.00 euros on Lang & Schwarz at 18:21 CET on Wednesday, November 11, 2026. Investors will now weigh the potential cost, remedy and management-time implications of the case alongside evidence of commercial execution in the group's businesses.

Next result date remains fixed

Givaudan's next scheduled full-year results are due on January 27, 2027. Those results should give investors a further reference point for operating performance while the US litigation continues.